GSK and Alector terminated a phase 2 Alzheimer’s disease program after an interim analysis indicated the trial would be unlikely to reach its primary endpoint. The decision followed the companies’ prior investment in the collaboration that anchored Alector’s Alzheimer’s efforts. The move highlights continued selectivity in late-stage resource allocation as Alzheimer’s studies remain difficult to translate into endpoint wins. For investors and partners, the halt underscores the importance of endpoint probability in Alzheimer’s trial design and interim monitoring.